Why Celladon Corp. Shares Are Pumped Up

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Celladon (NASDAQ: CLDN  ) , a clinical-stage biopharmaceutical company developing therapies to treat heart failure, jumped as much as 26% after receiving the highly coveted breakthrough therapy designation from the Food and Drug Administration for Mydicar.

So what: According to Celladon's press release, Mydicar, an experimental genetic enzyme replacement therapy used to correct a deficiency in the SERCA2a enzyme, was granted the breakthrough therapy designation "for reducing hospitalizations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb negative." The breakthrough designation will give Celladon the opportunity to work more closely with the FDA, and potentially speed up its review and development process. Mydicar is currently being evaluated in its phase 2b CUPID 2 study to determine its effectiveness at reducing the frequency of, and/or delaying, heart failure-related hospitalizations. The company expects to report its mid-stage results in April 2015.

Now what: The breakthrough therapy designation isn't a guarantee that a drug will be approved, so shareholders will want to keep that in mind. However, the crucial win for Celladon, should Mydicar perform as well as expected in reducing or delaying heart failure-related hospitalizations, is that its expedited review process could save millions in clinical trial costs. Initial results from its previously phase 2a CUPID 1 trial looked promising. Over the three-year follow-up period, the risk of cardiovascular events in the presence of terminal events was reduced by 82% with Mydicar viewed as safe and tolerable. In short, it's a small-cap stock worth keeping an eye on.

Celladon shares may have soared today, but even it could struggle to keep pace with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2910610, ~/Articles/ArticleHandler.aspx, 9/2/2015 3:06:35 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,240.54 182.19 1.13%
S&P 500 1,933.82 19.97 1.04%
NASD 4,700.34 64.24 1.39%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2015 2:50 PM
CLDN $1.17 Up +0.02 +1.74%